Cerebrolysin, 20 ml 5 pcs

Notropic drug.

Cerebrolysin contains low molecular weight biologically active neuropeptides, which penetrate through the BBB and directly reach the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.

Metabolic regulation: the drug Cerebrolysin increases the efficiency of aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.

Neuroprotection: the drug protects neurons from the damaging effects of lactacidosis, prevents the formation of free radicals, increases survival and prevents neuronal death under conditions of hypoxia and ischemia and reduces the damaging neurotoxic effects of excitatory amino acids (glutamate).

Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity similar to natural neural growth factors (NGF), but manifested under peripheral administration.

Functional neuromodulation: the drug has a positive effect in cognitive disorders on memory processes.

Indications

Alzheimer’s disease, Stroke sequelae, Acquired dementia, Learning disabilities, Headaches, Attention and memory disorders, Mental retardation in children, Depression, Asthenia, Concussion and other brain injuries.p> – Alzheimer’s disease;

– Dementia syndrome of various genesis;

– Chronic cerebrovascular insufficiency;

– ischemic stroke;

– traumatic brain and spinal cord injury;

– mental retardation in children;

– attention deficit disorder in children;

– endogenous depression resistant to antidepressants (as part of complex therapy).

Active ingredient

Brain Peptide Complex

Composition

1 ml – Cerebrolysin concentrate (peptide complex* derived from the pig brain) 215.2 mg

*molecular weight not exceeding 10,000 daltons.

Interaction

Taking into account the pharmacological profile of Cerebrolysin, special attention should be paid to possible additive effects when coadministered with antidepressants or MAO inhibitors. In such cases, it is recommended to reduce the dose of antidepressant. Administration of Cerebrolysin in high doses (30-40 ml) in combination with MAO inhibitors in high doses may cause an increase in BP.

Cerebrolysin and balanced amino acid solutions should not be mixed in the same infusion solution.

Cerebrolysin is not compatible with solutions that contain lipids and with pH-altering solutions (5.0-8.0).

.

Directions for use

The drug is administered parenterally. The dose and duration of administration depend on the nature and severity of the disease, as well as the age of the patient. A single administration of the drug in a dose of up to 50 ml is possible, but a course of treatment is preferable.

The recommended course of treatment is daily injections for 10-20 days.

To increase the effectiveness of treatment, repeated courses may be given as long as the patient’s condition is observed to improve due to treatment. After the first course, the frequency of injections may be reduced to 2 or 3 times per week.

Cerebrolysin is administered parenterally as an intravenous injection (up to 5 ml) and an intravenous injection (up to 10 ml). The drug in a dose of 10 ml to 50 ml is recommended to be administered only by slow IV infusions after dilution with standard solutions for infusion. The duration of infusion is 15 to 60 minutes.

.

Special Instructions

Injection too quickly may cause fever, sweating, and dizziness. Therefore, the drug should be administered slowly.

The compatibility of the drug has been tested and confirmed (for 24 hours at room temperature and lighting conditions) with the following standard solutions for infusion: 0.9% sodium chloride solution, Ringer’s solution, 5% dextrose solution (glucose).

Cerebrolysin may be used simultaneously with vitamins and drugs that improve cardiac circulation, but these drugs should not be mixed in the same syringe with Cerebrolysin.

Cerebrolysin clear solution should only be used and only once.

Impact on driving and operating machinery

Clinical studies have shown that Cerebrolysin has no effect on the ability to drive vehicles and operate machinery.

.

Contraindications

– severe renal failure;

– epileptic status;

– hypersensitivity to the drug.

With caution should the drug be used in case of allergic diathesis, diseases of epileptic character, including generalized epilepsy, due to possible increase in seizure frequency.

Side effects

The frequency of adverse reactions was determined in accordance with the WHO guidelines: very common: (≥1/10); common: (≥1/100 to

Immune system disorders: very rare – hypersensitivity, allergic reactions.

Mental disorders: rare – the supposed effect of activation is accompanied by agitation, manifested by aggressive behavior, confusion, insomnia.

Nervous system disorders: rarely – too rapid administration of the drug may lead to dizziness; very rare – isolated cases of generalized epilepsy and one case of seizures was associated with Cerebrolysin.

Cardiovascular system disorders: very rare – too rapid administration of the drug may lead to increased heart rate and arrhythmia.

Digestive system disorders: very rare – dyspepsia, diarrhea, constipation, nausea, vomiting; rarely – loss of appetite.

Skin and subcutaneous tissues: very rare – skin reactions; rare – fever, sweating, itching possible if injected too quickly.

General disorders and disorders at the injection site: very rare – redness, itching, burning at the injection site, pain in the neck, head and extremities, fever, mild back pain, shortness of breath, chills, collaptoid condition.

One study reported an association between use of the drug in rare cases (>1/10,000 to

Since Cerebrolysin is used primarily in older patients, the above disease symptoms are typical of this age group and often occur without taking the drug as well.

Please note that some adverse events (agitation, hypertension, hypotension, lethargy, tremor, depression, apathy, dizziness, headache, dyspnea, diarrhea, nausea) have been reported in clinical studies and occurred equally in patients receiving Cerebrolysin as in patients in the placebo group.

If any of the side effects listed in the instructions are aggravated or any other side effects not listed in the instructions are noted, the patient should tell the attending physician.

Notification if side effects are suspected

It is important to report side effects after the drug is registered to ensure ongoing monitoring of the risk/benefit ratio of the drug. Healthcare professionals are asked to report all adverse events observed while using the drug through national adverse reaction reporting systems and/or to the company’s representative office.

Overdose

No cases of overdose of Cerebrolysin have been reported.

Pregnancy use

Cerebrolysin should only be used during pregnancy and during breastfeeding after careful analysis of the correlation between the positive effects of the treatment and the risks associated with it.

The results of experimental studies do not suggest that Cerebrolysin has any teratogenic effect or toxic effect on the fetus.

There have been no similar clinical studies, however.